Gilead Sciences, Inc. revised earnings guidance for the fiscal year 2022. For the period, the company expects total product sales to be between $23.8 billion and $24.3 billion. EPS to be between $3.00 and $3.50, compared to $4.70 and $5.20 previously.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.78 USD | -0.84% | -0.98% | -20.03% |
02/05 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
01/05 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.03% | 80.78B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences, Inc. Revises Earnings Guidance for the Fiscal Year 2022